Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to Trade
COLL Q3 2026 deep dive: ADHD portfolio drives growth as pain business stabilizes
Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript
Collegium Pharmaceutical, Inc. 2026 Q3 - Results - Earnings Call Presentation
Collegium Pharmaceutical Inc (COLL) (Q3 2026) Earnings Call Highlights: ADHD Franchise Hits ...
Piper Sandler Maintains Neutral on Collegium Pharmaceutical, Lowers Price Target to $28
Collegium (COLL) Q3 2026 Earnings Call Transcript
Collegium Pharmaceutical Q3 Earnings Call Highlights
Collegium Pharmaceutical (NASDAQ:COLL) Posts Mixed Q3 as EPS Beats, Revenue Misses, and Guidance Holds
Collegium Pharmaceutical (NASDAQ:COLL) posts in line Q3 2026 sales and full year revenue guidance above estimates, stock soars
Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key Metrics
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $44
Collegium Pharmaceutical: Q3 Earnings Snapshot
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
Collegium Pharmaceutical Q3 2026 Earnings Call Transcript
Collegium Pharmaceutical Affirms FY2026 Sales Guidance of $825.000M-$855.000M vs $835.780M Est
Collegium Pharmaceutical Q3 Adj. EPS $1.96 Beats $1.86 Estimate, Sales $216.339M Miss $217.276M Estimate
COLL or SDZNY: Which Is the Better Value Stock Right Now?
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.